Disc Medicine Reports $62.3 Million Net Loss in Q3 2025, Driven by Increased R&D Expenses

Disc Medicine, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $62.3 million for the third quarter, compared to a loss of $26.6 million in the same period last year, marking an increase of 134%. For the nine months ended September 30, 2025, the net loss was $151.7 million, up from $79.9 million in the prior year. The increase in losses is attributed to heightened research and development expenses, which surged to $50.3 million in Q3 2025 from $24.7 million in Q3 2024, driven by costs associated with ongoing clinical trials and milestone payments.

Disc Medicine's total operating expenses for the third quarter reached $67.7 million, a substantial rise from $32.9 million in the previous year. The company’s research and development expenses accounted for the majority of this increase, reflecting its commitment to advancing its clinical pipeline, which includes bitopertin, DISC-0974, and DISC-3405. The company has not yet generated any revenue from product sales, as it remains focused on the development of its product candidates.

In terms of operational metrics, Disc Medicine reported cash, cash equivalents, and marketable securities totaling $615.9 million as of September 30, 2025. This figure includes net proceeds of approximately $210.9 million from an underwritten public offering completed in October 2025. The company anticipates that its existing cash reserves will be sufficient to fund its operations and capital expenditures into 2029, without accounting for potential revenues from product sales. The company’s employee headcount has also increased, reflecting its growth strategy and the need for additional personnel to support its expanding clinical programs.

Strategically, Disc Medicine has made significant progress in its clinical trials, including the initiation of the APOLLO trial for bitopertin, which is designed to support a potential accelerated approval pathway. The company has also received a Commissioner’s National Priority Voucher from the FDA, which may expedite the review process for its NDA submission for bitopertin. However, the company faces ongoing risks, including the need for additional funding to support its development programs and the potential for delays in clinical trial enrollment and regulatory approvals.

Looking ahead, Disc Medicine remains focused on advancing its clinical programs while navigating the complexities of regulatory requirements and market competition. The company’s ability to successfully develop and commercialize its product candidates will be critical to its future financial performance and overall viability in the biopharmaceutical market.